The US Food and Drug Administration’s review and approval of Moderna, Inc.’s COVID-19 vaccine Spikevax reflected the uncertainties of the evidence amid an evolving pandemic, notably the emergence of the Omicron variant.
The biologics license application was submitted to the agency on 24 August, at which time the Delta variant was predominant...